Insights | Analysis of the development of biopharmaceutical industry in Yantai City

Sun Xiaoyang biomedical health industry is a national strategic emerging industry, but also known as "the sunrise industry that will never decline", in recent years, Yantai Municipal Government established the "to build a hundred billion-level pharmaceutical and health industry, the construction of international life science innovation demonstration zone" development goals.
October 2019, the National Development and Reform Commission issued a Notice on Accelerating the Construction of Strategic Emerging Industrial Clusters, announcing the first batch of 66 national-level strategic emerging industrial clusters, 17 of which are biopharmaceutical industry clusters.
, Yantai City biopharmaceutical industry was successfully selected, ranked first in the field of biopharmaceuticals, for Yantai City to develop biopharmaceutical industry has brought new historical opportunities.
, industrial scale in recent years, Yantai Biomedical Health industry is booming.
2018, Yantai pharmaceutical manufacturing industry output value of 19.78 billion yuan, 120 enterprises, Yantai Biopharmaceutical industry achieved total revenue of 83.318 billion yuan, up 13.3% YoY.
, the number of Yantai medical and health enterprises 16,885, the national pharmaceutical industry top 100 enterprises (Green Leaf Investment Group) 1.
Green Leaf Life Group, Dongcheng Pharmaceuticals and Penglenokang entered the 2019 National Top 100 Chemical Drugs; Ruikang Pharmaceuticals ranked among the top 500 Chinese enterprises in 2019, ranking among the top seven pharmaceutical businesses in China; Rongchang Bio became the top 100 Pharmaceutical Innovation Enterprises in China in 2019; and emerging emerging enterprises such as Shi medicine Baike and Mei Bairui have grown rapidly and have become key enterprises in the sub-sector.
figure 1: Yantai City pharmaceutical industry top 100 and listed enterprises listed photo source: Firestone creation data factory II, industrial chain Yantai City biopharmaceutical health industry formed a medical devices, chemicals as the basis for the development of biological drugs, traditional Chinese medicine, medical services and other multi-line industrial system.
Among them, the API intermediates mainly rely on Yixin Fine Chemical, Chu Pharmaceuticals, chemical drugs mainly rely on Green Leaf Dongcheng Pharmaceuticals, Penglenokang, Huino Pharmaceuticals, Chinese medicine mainly rely on Rongchang Pharmaceuticals, Rongchang Pharmaceuticals and Shengu Pharmaceuticals, medical devices mainly rely on Zheng Sea biology, Yan Xiu biology; biopharmaceuticals mainly rely on Rongchang biological, sonic biology and stone pharmaceutical group Baike (Shandong) biology; pharmaceutical commercial circulation enterprises mainly have Ruikang pharmaceutical, Bentai medical, Industryda medicine; and enterprises engaged in outsourcing services such as: Mei Bairui and so on.
figure 2: Qingdao, Shandong Province, biopharmaceutical industry key institutions / enterprises (part) Photo source: Firestone Creative Data Factory III, the space chain Yantai City to the international life science innovation demonstration zone as the leader, planning and construction of biopharmaceutical industry park, international biopharmaceutical innovation industrial park, Chinese medicine and precision medicine industrial park, pharmaceutical and health industrial park, biomedical and health industrial park, medical equipment logistics and pharmaceutical industry park seven parks, the formation of the "seven parks".
the main cluster areas are Muping District, High-tech Zone, Economic Development Zone.
figure 3: Yantai Biopharmaceutical Health Industry Space Layout Photo Source: Firestone Creation according to public information finishing (1) Economic Development Zone 1. Industrial base relying on Rongchang Pharmaceutical, Proji Company, Dongcheng Biochemical, Medzin and other biopharmaceutical enterprises are building Yantai International Biopharmaceutical Valley into the most important "biopharmaceutical valley" in northern China, the initial formation of biopharmaceuticals, modern Chinese medicine, biochemicals, medical equipment and other four major areas, annual output value of more than 40 billion yuan.
Up to now, there have been 41 biopharmaceutical enterprises settled, Proji, Dongcheng Pharmaceuticals, Mei Bairui and other 29 projects completed and put into operation, a total investment of 15.3 billion yuan Zhenghai Biological, Rongchang Bio-New Drug industrialization and other 12 projects are under construction, showing a "put into production, in the construction of a batch, start a batch, reserve a batch" development pattern.
2. The main space carrier (1) International Merchants Industrial Park marine life and medical and health industry cluster area relying on biomedical park, the East Island science and education corridor, to support the original biopharmaceutical enterprises and innovative research and development platform to become bigger and stronger, the introduction of a number of high-level, international biopharmaceutical research and development and industrialization projects, to create a world-class biopharmaceutical valley, while accelerating the promotion of modern marine fisheries, marine drug development and other marine projects, the introduction of foreign marine biological extraction, deep processing and other enterprises.
(2) Yantai IndustryDa International Biopharmaceutical Innovation Incubation Center Yantai Industry International Biopharmaceutical Innovation Incubation Center by Yantai Development Zone Management Committee and Rongchang Pharmaceutical funding, jointly build more than 50,000 square meters of biomedical incubation carrier.
project has an animal laboratory center, diagnostic reagent laboratory, biological medicine test workshop, antibody research and development public laboratory, experimental instruments public platform and standard biological laboratory incubation unit, can accommodate nearly 100 research and development units.
positioning is to build a professional biomedical science and technology innovation and achievement transformation platform with international level.
(ii) High-tech Zone 1. Industrial base In recent years, Yantai High-tech Zone in the pharmaceutical and health industry has made remarkable achievements, at present, there are more than 80 pharmaceutical and health enterprises in the region, "four on" enterprises 5, the development and expansion of the pharmaceutical and health industry, high-tech zone advantages are obvious, the foundation is strong. Over the past
years, the high-tech zone has cultivated a number of industry backbone enterprises, green leaf pharmaceutical, Saichun medicine, National Pharmaceutical Holdings, Connoxon and other marine life and health-related product development, production and supporting enterprises to form the whole industry chain ecology, products covering biopharmaceuticals, medical devices, diagnostic reagents and vaccines, bio-health products and other fields.
, Green leaf pharmaceutical is committed to anti-tumor, central nervous system, cardiovascular, diabetes and other fields of innovative drug research and development, production and sales, selected as "pharmaceutical listed companies research and development innovation strength of the top 10."
2. The main space carrier (1) Shandong International Biotech Park to build Yantai International Pharmaceutical Health and Health Industry Innovation Center, the center is a collection of medical health research and development, special medical services, medical and health integration and other multi-functional in one of the world's first-class science and technology park;
(2) Yantai International Merchants Industrial Park to form a marine medicine health research and development features, pharmaceutical manufacturing and medical device manufacturing as the main force, to pharmaceutical circulation and health management services as the advantage of the large health ecological industry cluster area.
and results transformation platform.
(iii) Muping District 1. Industrial base "Yantai Blue Drug Valley" project total investment of about 8 billion yuan, covers an area of about 1500 acres, has been built and introduced stone medicine (100 grams), Fengjin medicine, Fuhai medicine package and other projects, the aggestosity effect initially appeared, the development platform of the pharmaceutical and health industry initially formed.
Relying on existing projects, we will focus on cutting-edge technologies, frontier areas and cutting-edge models such as new biotechnology drugs and new medical polymer materials, and vigorously develop biomedicine and large-scale health industries around the four areas of biomedicine, medical devices, health care products and marine health products, high-tech pharmaceutical research and development and outsourcing of industrialization services, and strive to build hundreds of billions of industrial clusters.
In 2019, the main business income of the pharmaceutical industry in the whole region was over 3 billion yuan, with nearly 300 million yuan in taxes, and the whole industrial chain of drug research and development, production and sales was initially opened, and the amassing effect was initially apparent, and the development platform of the pharmaceutical and health industry was initially formed.
, is tracking the promotion of Hengrui Pharmaceuticals, Green Leaf Pharmaceuticals and other projects, will comprehensively build a new map of the wisdom Yantai Pharmaceutical Valley.
2. Main Space Carrier (1) Seine Korea Industrial Park: Focus on four sub-areas: biopharmaceuticals, medical devices, health care products and marine health products, pharmaceutical research and development and outsourcing of industrialization services.
(2) Hengbang Chemical Industry Park: focusing on the field of API and pharmaceutical intermediates.
(3) Yantai International Merchants Industrial Park: focusing on marine life and medical and health care.
4, innovation chain 1. Innovation elements according to public information shows that Yantai City has gathered a number of industry leaders to provide sustained impetus for the development of the biopharmaceutical industry.
Relying on high-end talent, Yantai City has built a national comprehensive new drug research and development technology platform demonstration enterprises 4, national key laboratories, engineering laboratories, identified enterprise technology centers and foreign academicians workstations each 1, post-doctoral mobile stations 2, provincial enterprise technology centers 3, provincial engineering and technology research centers 7, for industrial innovation to provide adequate technical support and space carrier.
2. Innovation Capital according to Firestone Creation Database data show that so far, Yantai City publicly disclosed the total amount of financing of the biopharmaceutical industry 4.4 billion yuan.
3. Innovation results according to firestone creation database data show that up to now, Yantai City listed two or three types of medical devices 246, 805 domestic drugs approved, the number of domestic invention patents 995, CDE acceptance of I. , II. class 184 new drugs.
. In order to speed up the construction of the biopharmaceutical industry and optimize the industrial development environment, Yantai City has issued the Implementation Opinions on Promoting the Innovation and Development of the Pharmaceutical Health Industry and Building the International Life Sciences Innovation Demonstration Zone, the Regulations on the Implementation of the Incentives for Innovative Products of Drugs and Medical Devices in Yantai City (Trial), and Yantai Biopharmaceutical Industry Cultivation and Development Promotion Program, on further support for the city's biopharmaceutical industry innovation and development of supplementary advice and other specific measures documents, Yantai City Biopharmaceutical Industry Development Plan 2020-2025 is being further revised and improved.
Yantai to major projects as a carrier, scientific and technological innovation as the driving force, high-end platform as a support for the biomedical health industry to increase policy support, and constantly stimulate the vitality of industrial innovation, to promote the industry's sustained healthy and high-quality development.
6. Summary and recommendations, Yantai City biopharmaceutical industry has a strong foundation, expanding industrial scale, complete industrial chain system, leading manufacturing scale, significant innovation results, but still face the lack of high-end innovation subject, insufficient coordination between production, research and development and cluster advantages can not be fully developed and other issues.
In order to realize the transformation from industrial chain layout to industrial ecological layout, Yantai will focus on industrial upgrading, accelerate the cultivation of leading backbone enterprises, strengthen cooperation between industry, research and development and upstream and downstream enterprises, and build a sound biopharmaceutical industry system.
with the continuous improvement of the industrial service platform, biopharmaceutical high-tech research and development enterprises will accelerate to Yantai gathering.
The "14th Five-Year Plan" period will be a period of great breakthrough, structural adjustment and energy level improvement of the pharmaceutical industry, Yantai City should not miss the opportunity to adjust and optimize its own industrial structure, find the right power point, to achieve the great development of the pharmaceutical industry.
1. Find the right position in the industry gradient difference, strengthen the development prospects of the top-level design, and lay the foundation for the rise of the biopharmaceutical industry in Yantai City.
the future, Yantai needs to further clarify the positioning, strengthen the top-level design, identify the key development of industrial sub-sectors, and form a distinct industrial identity.
At the same time, the resources of each district should be combed in detail, the regions form a differentiated, characteristic functional positioning, pharmaceutical sub-sectors of industrial clusters in a broader range to achieve capital, technology, talent, platform and other efficient allocation.
. Taking marine biopharmaceuticals as an important development increment to promote the upgrading of industrial structure and the development of marine biotechnology, and promote the rise of marine biopharmaceuticals and products industry, marine biopharmaceuticals and products industry clusters have been initially formed.
has emerged a number of high-quality biopharmaceous enterprises such as Dongcheng Pharmaceuticals, Rongchang Bio, Synth Madzin, Fengjin Bio, Shi medicine Baike (Shandong).
From the point of view of technological trends, genetic engineering technology provides a new way to develop biometric drugs, synthetic biotechnology applies synthetic genes, bacteria, mRNA, immunological devices, etc. to disease research and treatment, and stem cell technology will focus on research models, cell therapy, and organ regeneration.
breakthrough in biopharmace product technology will promote the rapid development of the industry, Yantai should grasp the strategic opportunity period of a new round of biopharmaceers, vigorously develop antibodies, vaccines, protein drugs and other biopharmaceers industries, and promote the upgrading of industrial structure.
3. To promote the domestic medical device industry of high-end medical devices has become the focus area of competing development in various places, and the level of medical device manufacturing also represents the level of industrial technology in a region to a certain extent.
Yantai medical device industry accounted for a higher proportion of the entire biopharmaceutical sector, the development of a better foundation, so Yantai to high-end medical device development as a top priority to grasp, seize the domestic medical devices are entering the middle-end products mainly to high-end product development, from small to large, from weak to strong new opportunities, vigorously promote the development and manufacture of high-end domestic medical devices, enterprises as the main body, market-oriented to build domestic high-end medical devices commanding heights.
. To digitalize the industry as a bioethic empowerment, to enhance the innovation efficiency of enterprises active capital, strong enterprises, leading talents, innovation source is the biopharmaceutical industry advantages established factor conditions.
The integration of digital economy and bio-economy transforms the path and way of convergence factors, on the one hand, expanding the edge of the pharmaceutical industry, intelligent medical, Internet medical and other emerging industries, on the other hand, improving the resource aggregation efficiency and research and development efficiency of the pharmaceutical industry.
Yantai should take industrial digitalization as the bio-economic empowerment, break through the existing industrial growth rate and resource factor bottleneck, and open up a new high-speed channel for medical economic development.